CCC Project- Acute Coronary Syndrome

Acute Coronary Syndrome Clinical Trial

Official title:

Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Acute Coronary Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02306616
• Other study ID #: CCC-ACS-2014
• Status: Completed
• Start date: November 2014
• Est. completion date: December 2020

Study information

• Verified date: January 2021
• Source: Beijing Institute of Heart, Lung and Blood Vessel Diseases
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

To develop and implement quality improvement programs for the treatment of acute coronary syndrome (ACS) in China based on the successful experience of the AHA-Get with the Guidelines program. This program will use data collection, analysis, feedback, and process improvement to extend the use of evidence-based guidelines throughout the healthcare system and improve patient care of acute coronary syndrome.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124363
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Hospitalized patients with discharge diagnosis as acute coronary syndrome (including STEMI, NSTEMI and UAP) in 150 tertiary and 100 secondary hospitals.

Exclusion Criteria:

None

Related Conditions & MeSH terms

• Acute Coronary Syndrome
• Syndrome

Locations

Country	Name	City	State
China	Beijing An Zhen Hospital	Beijing

Sponsors (3)

Lead Sponsor	Collaborator
Beijing Institute of Heart, Lung and Blood Vessel Diseases	American Heart Association, Chinese Society of Cardiology

Country where clinical trial is conducted

China, 

References & Publications (7)

Hao Y, Liu J, Liu J, Smith SC Jr, Huo Y, Fonarow GC, Ma C, Ge J, Taubert KA, Morgan L, Guo Y, Zhang Q, Wang W, Zhao D; CCC-ACS Investigators. Rationale and design of the Improving Care for Cardiovascular Disease in China (CCC) project: A national effort t — View Citation

Hao Y, Liu J, Liu J, Yang N, Smith SC Jr, Huo Y, Fonarow GC, Ge J, Taubert KA, Morgan L, Zhou M, Xing Y, Ma CS, Han Y, Zhao D. Sex Differences in In-Hospital Management and Outcomes of Patients With Acute Coronary Syndrome. Circulation. 2019 Apr 9;139(15) — View Citation

Xing Y, Liu J, Hao Y, Liu J, Huo Y, Smith SC Jr, Ge J, Ma C, Han Y, Fonarow GC, Taubert KA, Morgan L, Yang N, Zhou M, Zhao D; CCC-ACS Investigators. Prehospital statin use and low-density lipoprotein cholesterol levels at admission in acute coronary syndr — View Citation

Yang N, Liu J, Liu J, Hao Y, Huo Y, Smith SC Jr, Ge J, Ma C, Han Y, Fonarow GC, Taubert KA, Morgan L, Zhou M, Xing Y, Zhao D; CCC-ACS Investigators. Performance on management strategies with Class I Recommendation and A Level of Evidence among hospitalize — View Citation

Yang Q, Wang Y, Liu J, Liu J, Hao Y, Smith SC Jr, Huo Y, Fonarow GC, Ma C, Ge J, Taubert KA, Morgan L, Guo Y, Wang W, Zhou Y, Zhao D; CCC-ACS Investigators. Invasive Management Strategies and Antithrombotic Treatments in Patients With Non-ST-Segment-Eleva — View Citation

Zhao G, Zhou M, Ma C, Huo Y, Smith SC Jr, Fonarow GC, Ge J, Han Y, Liu J, Hao Y, Liu J, Wang X, Taubert KA, Morgan L, Zhao D, Nie S; CCC-ACS Investigators. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute — View Citation

Zhou M, Liu J, Hao Y, Liu J, Huo Y, Smith SC Jr, Ge J, Ma C, Han Y, Fonarow GC, Taubert KA, Morgan L, Yang N, Xing Y, Zhao D; CCC-ACS Investigators. Prevalence and in-hospital outcomes of diabetes among patients with acute coronary syndrome in China: find — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The overall composite of 11 performance measures for ACS care	Performance measures for ACS care including: Proportion of patients received aspirin at arrival; Proportion of patients received fibrinolytic therapy within 30 mins (STEMI); Proportion of patients received primary percutaneous coronary intervention within 90 mins (STEMI); Proportion of patients received reperfusion therapy (STEMI); Proportion of patients with aspirin prescribed at discharge; Proportion of patients with clopidogrel or other P2Y12 inhibitors prescribed at discharge; Proportion of patients with beta-blocker prescribed at discharge; Proportion of patients with statin prescribed at discharge; Proportion of patients received evaluation of left ventricular systolic function; Proportion of left ventricular systolic dysfunction patients with ACEI or ARB prescribed at discharge; Proportion of patients received smoking cessation advice/ counseling	Duration of hospital stay, an expected average of 1 week

External Links

•   Website of the study (in Chinese)